Tina M Mayer
Overview
Explore the profile of Tina M Mayer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
71
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Allaf M, Kim S, Master V, Mcdermott D, Harshman L, Cole S, et al.
Lancet Oncol
. 2024 Jun;
25(8):1038-1052.
PMID: 38942046
Background: The standard of care for patients with intermediate-to-high risk renal cell carcinoma is partial or radical nephrectomy followed by surveillance. We aimed to investigate use of nivolumab before nephrectomy...
2.
Lichtbroun B, Shinder B, Sara T, Srivastava A, Saraiya B, Mayer T, et al.
J Kidney Cancer VHL
. 2023 Jul;
10(3):1-8.
PMID: 37441361
Chromophobe renal cell carcinoma (chRCC) is one of the less common types of kidney cancer and generally portends a more favorable prognosis. RCC with sarcomatoid differentiation has a more aggressive...
3.
Rizvi F, Korst M, Young M, Habib M, Kra J, Shah A, et al.
J Cancer Educ
. 2023 Mar;
38(5):1466-1470.
PMID: 36905555
Palliative radiation therapy (PRT) is underutilized, partially due to misconceptions about its risks, benefits, and indications. The objective of this pilot study was to determine if patients with metastatic cancer...
4.
Shinder B, Kim S, Srivastava A, Patel H, Jang T, Mayer T, et al.
Urol Oncol
. 2023 Mar;
41(4):208.e1-208.e8.
PMID: 36868881
Objective: Recruitment of a diverse and representative study population is critical to the external validity of oncology clinical trials. The primary objective of this study was to characterize the factors...
5.
Yoshitake S, Shinder B, Dazen K, Smith C, Mayer T, Sadimin E, et al.
J Kidney Cancer VHL
. 2022 Sep;
9(2):22-26.
PMID: 36118790
Renal cell carcinoma (RCC) metastases to the testicle are an extremely rare clinical entity. Here, we describe the case of a man with metastatic RCC who developed a new testicular...
6.
Patel H, Kim S, Srivastava A, Shinder B, Sterling J, Saraiya B, et al.
Clin Genitourin Cancer
. 2022 Feb;
20(3):296-296.e9.
PMID: 35105510
Introduction: Several guidelines have adopted early integration of palliative intervention (PI) into oncologic care to improve quality of life among patients with advanced malignancies. However, PI utilization patterns and factors...
7.
Autio K, Antonarakis E, Mayer T, Shevrin D, Stein M, Vaishampayan U, et al.
Eur Urol Open Sci
. 2021 Dec;
34:70-78.
PMID: 34934969
Background: Phase 2 trial endpoints that can be utilized in high-risk biochemical recurrence (BCR) after prostatectomy as a way of more rapidly identifying treatments for phase 3 trials are urgently...
8.
Shiuan E, Reddy A, Dudzinski S, Lim A, Sugiura A, Hongo R, et al.
Cancers (Basel)
. 2021 Apr;
13(6.
PMID: 33806963
Predicting response to ICI therapy among patients with renal cell carcinoma (RCC) has been uniquely challenging. We analyzed patient characteristics and clinical correlates from a retrospective single-site cohort of advanced...
9.
Srivastava A, Rivera-Nunez Z, Kim S, Sterling J, Farber N, Radadia K, et al.
Cancer
. 2020 Apr;
126(13):2991-3001.
PMID: 32329899
Background: Stage III renal cell carcinoma (RCC) encompasses both lymph node-positive (pT1-3N1M0) and lymph node-negative (pT3N0M0) disease. However, prior institutional studies have indicated that among patients with stage III disease,...
10.
Munshi F, Shinder B, Sadimin E, Mayer T, Singer E
Cancer Stud Ther
. 2020 Mar;
4(4).
PMID: 32148662
Prostate cancer metastases are commonly seen in the skeleton, lymph nodes, lungs, or liver, and are associated with a poor five-year survival rate. Renal pelvis and ureteral metastasis are exceedingly...